Apollomics Inc. (NASDAQ:APLM) Short Interest Down 15.2% in February

Apollomics Inc. (NASDAQ:APLM) saw a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling 12,471 shares, a decrease of 15.2% from the February 12th total of 14,705 shares. Based on an average daily volume of 5,401 shares, the days-to-cover ratio is currently 2.3 days. Approximately 1.1% of the company’s stock are sold short. Approximately 1.1% of the company’s stock are sold short. Based on an average daily volume of 5,401 shares, the days-to-cover ratio is currently 2.3 days.

Analyst Ratings Changes

A number of research firms have issued reports on APLM. Wall Street Zen raised Apollomics from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Apollomics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Institutional Trading of Apollomics

A hedge fund recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC acquired a new position in shares of Apollomics Inc. (NASDAQ:APLM) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned approximately 0.40% of Apollomics as of its most recent filing with the SEC. 19.13% of the stock is owned by institutional investors and hedge funds.

Apollomics Trading Up 0.5%

Shares of APLM stock opened at $19.90 on Monday. The firm has a fifty day moving average price of $19.96 and a 200 day moving average price of $17.73. Apollomics has a 12 month low of $3.66 and a 12 month high of $42.12.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.